PharmTech News

Articles

CHMP recommended the approval of AbbVie’s RINVOQ (upadacitinib) as a treatment for adults with moderate-to-severe Crohn’s disease.

AbbVie Receives Positive CHMP Opinion for Crohn’s Disease Treatment

Orchard Therapeutics has announced an agreement which will enable reimbursed access to Libmeldy for all eligible MLD patients in Sweden.

Orchard Therapeutics to Reimburse Access to Libmeldy for MLD Patients in Sweden

Roche’s Phase III global program, centered around the biologic crovalimab as a treatment for paroxysmal nocturnal haemoglobinuria, showed the drug was non-inferior to current standards of care.

Roche Reports Positive Data for Rare Blood Condition Treatment

iotaSciences isoPick is designed to expand handling solutions for cell biology and gene therapy applications.

iotaSciences Launches Single-Cell Picker

Editor of Pharmaceutical Technology Europe

The European bio/pharma industry’s high regulatory standards and GMP requirements are set to position the region as a frontrunner for pharmaceutical‑grade manufacturing of cannabis-based medicines.

Advantageous Positioning for Europe in Pharmaceutical Cannabis

Although some headway is being made into more gender-diverse executive levels in pharma, much more work is still needed.

Improving Gender Diversity

CRB’s latest industry report includes an expanded audience to include many European countries, which has provided some interesting insights.

Providing a Snapshot of the Industry

Chiesi will acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in a deal worth up to $1.47 billion.

Chiesi Acquires Rare Diseases Company in $1.47 Billion Deal

The company was awarded the Terra Carta Seal in recognition of its commitment to creating a sustainable future. 

Samsung Biologics Receives the Terra Carta Seal

Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.

PharmTech Europe News